Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment

Daichi Tsukada, Katsumi Iizuka, Ken Takao, Yanyan Liu, Sodai Kubota, Saki Okamoto-Kubota, Teruaki Sakurai, Toshinori Imaizumi, Mayu Sakai, Takehiro Kato, Masami Mizuno, Takuo Hirota, Tetsuya Suwa, Yukio Horikawa, Mayumi Yamamoto, Sumihisa Kubota, Daisuke Yabe

Research output: Contribution to journalArticlepeer-review

Abstract

We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia.

Original languageEnglish
Pages (from-to)2753-2757
Number of pages5
JournalInternal Medicine
Volume61
Issue number18
DOIs
Publication statusPublished - 2022

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment'. Together they form a unique fingerprint.

Cite this